If the MCM/CMG reserves are already debilitated due to Myc’s actions, then administering a CMGi has the propensity to make a bad situation worse, further inactivating the remaining (now limited) reserve CMG helicases and likely increasing the sensitization of tumor cells to fork stalling chemotherapy (Figure 2). This evidence concerns the gene MYC and neoplasm.